RxDoctor Payments Data

Jude Sidari, MD

Internal Medicine · Hazleton, PANPI 1700825452

Payments from drug & device makers

$29,068in general payments, 2019–2025

Across 1,991 payments — averaging $14.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Novo Nordisk$3K
  • AbbVie$2K
  • Boehringer Ingelheim$2K
  • Pfizer$2K
  • GSK$2K
  • plus $15K from 48 others

What the payments were for

  • Food & beverage$28,65199%
  • Education$4171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca166$3,283
Novo Nordisk173$2,658
AbbVie(2 entities)187$2,303
Boehringer Ingelheim114$1,940
Pfizer162$1,927
GSK106$1,616
Amgen104$1,535
Merck79$1,176
Teva Pharmaceuticals USA, Inc.86$1,099
Lilly USA, LLC79$1,037
Johnson & Johnson106$1,025
Takeda Pharmaceuticals U.S.A., Inc.64$874
Bayer52$759
Sanofi-aventis U.S. LLC50$610
E.r. Squibb & Sons, L.L.C.40$572
Paratek Pharmaceuticals, Inc.46$534
Astellas Pharma US Inc19$484
Amarin Pharma, Inc.31$474
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)26$454
Novartis28$431
Lundbeck LLC24$411
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC23$346
Otsuka America Pharmaceutical, Inc.17$314
Kowa Pharmaceuticals America, Inc.29$312
Phathom Pharmaceuticals, Inc.12$199
Radius Health, Inc.14$197
Shield Therapeutics Inc11$193
Vanda Pharmaceuticals Inc.11$188
Xeris Pharmaceuticals, Inc.11$187
Exact Sciences10$181
Abbott10$178
Axsome Therapeutics, Inc.12$173
Sumitomo Pharma America, Inc.12$163
Biohaven Pharmaceuticals, Inc.12$159
Esperion Therapeutics, Inc.10$133
Biogen6$120
Aimmune Therapeutics, Inc.7$115
Biohaven Pharmaceutical Holding Company Ltd.6$95
Sunovion Pharmaceuticals Inc.6$88
Eisai Inc.5$86
Dexcom, Inc.3$59
Ardelyx, Inc.3$54
Idorsia Pharmaceuticals US Inc3$47
Otsuka Pharmaceutical Development & Commercialization, Inc.2$47
Nestle Healthcare Nutrition Inc.2$40
Melinta Therapeutics, LLC2$33
Verona Pharma, Inc.2$30
Philips North America LLC2$27
Axonics, Inc.1$24
Scpharmaceuticals Inc.1$22
Seqirus USA Inc1$16
Shire North American Group Inc1$16
Corcept Therapeutics1$15
Biodelivery Sciences International, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,068 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$324,665
Medicare patients
440
Services billed
6,954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide452$472,342
JardianceEmpagliflozin497$328,263
EliquisApixaban402$244,218
RexultiBrexpiprazole101$149,732
Trelegy ElliptaFluticasone/Umeclidin/Vilanter183$137,224
FarxigaDapagliflozin Propanediol165$100,984
HumiraAdalimumab11$74,696
XareltoRivaroxaban93$60,429
RybelsusSemaglutide45$58,044
VraylarCariprazine Hcl49$54,920
JanuviaSitagliptin Phosphate59$52,746
LinzessLinaclotide89$52,240
MyrbetriqMirabegron110$51,323
TradjentaLinagliptin94$49,807
Tresiba Flextouch U-100Insulin Degludec77$45,160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,658$530,385497 claims
Boehringer IngelheimJardiance, Tradjenta$1,940$378,070591 claims
PfizerEliquis$1,927$244,218402 claims
AbbVieHumira, Vraylar, Linzess, Synthroid$2,303$191,057303 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,616$179,828256 claims
Otsuka America Pharmaceutical, Inc.Rexulti$314$149,732101 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$3,283$126,682219 claims
Johnson & JohnsonXarelto$1,025$60,42993 claims
Lilly USA, LLCTrulicity, Mounjaro$1,037$53,46240 claims
MerckJanuvia$1,176$52,74659 claims
Astellas Pharma US IncMyrbetriq$484$51,323110 claims
BayerKerendia$759$33,79848 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Hazleton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →